Know Cancer

or
forgot password

Semen Analysis Following Definitive Treatment of Prostate Cancer With Proton Radiation Therapy Alone


N/A
18 Years
N/A
Open (Enrolling)
Male
Prostate Cancer

Thank you

Trial Information

Semen Analysis Following Definitive Treatment of Prostate Cancer With Proton Radiation Therapy Alone


Inclusion Criteria:



- Diagnosis of low to intermediate risk prostate cancer and elected to have proton
radiation therapy at University of Florida Proton Therapy Institute (UFPTI).

Exclusion Criteria:

- Current use of Flomax, Hytrin, Cardura, Uroxatral, or Rapaflo.

- History of vasectomy.

- Current use of Lupron, Zoladex, Trelstar, Casodex, Eulexin.

- Current use of Avodart or Proscar.

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

Post treatment sperm count

Outcome Time Frame:

12 months after radiation therapy

Safety Issue:

No

Principal Investigator

Bradford S Hoppe, MD, MPH

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Florida Proton Therapy Institute

Authority:

United States: Institutional Review Board

Study ID:

UFPTI-0908-PR08

NCT ID:

NCT01072513

Start Date:

March 2010

Completion Date:

January 2018

Related Keywords:

  • Prostate Cancer
  • Semen Analysis, Prostate Cancer, Proton Radiation
  • Prostatic Neoplasms

Name

Location

University of Florida Proton Therapy InstituteJacksonville, Florida  32206